Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers

Abstract Background Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of patients with HR+/HER2– breast cancer. Preclinically, cancer cells harboring double or multiple PIK3CA mutations (mut...

Full description

Bibliographic Details
Main Authors: Katherine E. Hutchinson, Jessica W. Chen, Heidi M. Savage, Thomas J. Stout, Frauke Schimmoller, Javier Cortés, Susan Dent, Nadia Harbeck, William Jacot, Ian Krop, Sally E. Trabucco, Smruthy Sivakumar, Ethan S. Sokol, Timothy R. Wilson
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Genome Medicine
Subjects:
PIK3CA
Double PIK3CA mutation
Clonal
Taselisib
PI3K inhibitor
Breast cancer
Online Access:https://doi.org/10.1186/s13073-023-01181-8

Internet

https://doi.org/10.1186/s13073-023-01181-8

Similar Items